We’ve launched our latest Technology Journal: advances in human iPSC-derived models and NAMs for predictive, physiologically relevant research. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Newsletter Axol Bioscience

  

Welcome to the latest Axol Bioscience newsletter! May has been a busy and energising month for our team, filled with scientific exchange and innovation during a packed conference season. We’ve connected with the global research community at key events, including ARVO in Denver, ELRIG: Advances in Cell-based Screening in Gothenburg, Target ALS in Boston, the Huntington’s Disease Awareness Month event hosted by Harness Therapeutics in Cambridge, and the MPS World Summit in Washington, D.C. With May marking both Huntington’s Disease and ALS Awareness Month, it’s been a meaningful time to engage with these communities and highlight the importance of advancing research.

 

Continue reading to discover the exciting developments that have kept us hopping throughout May and to learn about upcoming opportunities to connect with our experts.

 

Key highlights in May

 

  1. 1. Utility of iPSCs on high-throughput platforms and how it supports NAMs
  2. 2. More than HD - Be Part of It | Huntington’s Disease Awareness Month 2026
  3. 3. Make ALS livable and cure it | ALS Awareness Month 2026
  4. 4. Axol Bioscience joins the British Chambers of Commerce Trade Accelerator programme
  5. 5. iPSC-derived cardiomyocytes for drug discovery, research and cardiotoxicity studies
  6. 6. Where you can find the Axol team

 

 

Utility of iPSCs on high-throughput platforms and how it supports NAMs

 

We’ve launched our latest Technology Journal, highlighting advances in human iPSC-derived models and New

Approach Methodologies (NAMs) for predictive, physiologically relevant research.

Thank you to our collaborators who are working on breaking new ground in new approach methodologies: Optics 11 Life, 3Brain, Nanion Technologies, innovitro, Sophion Bioscience.

 

 

More than HD - Be Part of It | Huntington’s Disease Awareness Month 2026

 

Understanding early‑onset Huntington’s disease (HD) requires models that truly reflect the biology driving the most severe forms of the condition. Our ax3219 HD striatal neuron kit provides exactly that.

 

Derived from the CENSOi019‑B line, these cells originate from a female donor aged 7, carrying HTT CAG14/CAG125 repeats, a genotype typical of early‑onset HD. This line demonstrates somatic CAG repeat instability, a key modifier of disease onset and progression, and now shows CAG143 after continued expansion in vitro.

 

 

Make ALS livable and cure it | ALS Awareness Month 2026

With limited treatment options and a growing need for better translational models, human iPSC-derived systems are increasingly important for advancing ALS research and drug discovery.

Our human iPSC-derived ALS models have been developed to do exactly that.

Built using motor neurons and microglia from both healthy and patient donors, these cells retain the genetic background and disease characteristics that drive ALS progression. Motor neurons are functionally active within 10 days and express key markers, including HB9 and ChAT, while supporting assays such as electrophysiology and calcium imaging.

 

 

 

Axol Bioscience joins the British Chambers of Commerce Trade Accelerator programme

 

We’re pleased to have been welcomed to the cohort of the British Chambers of Commerce Trade Accelerator programme.

At Axol Bioscience, we develop human iPSC-derived cell models and tools to enable disease modeling, drug discovery, and translational research across multiple therapeutic areas. Participation in the Trade Accelerator supports our ambition to scale these capabilities internationally and contribute to the global life sciences ecosystem from a strong UK foundation.

 

 

iPSC-derived cardiomyocytes for drug discovery, research and cardiotoxicity studies

Our highly validated, chamber-specific cardiomyocytes exhibit distinct atrial or ventricular pharmacology and phenotypes, generated from both female and male donors. 

  • * Spontaneously beat 3 days post‑thaw and are assay‑ready in just 7 days
  • * Ventricular cardiomyocytes are validated against all 28 CiPA compounds
  • * Atrial cardiomyocytes demonstrate functional responses to atrial‑specific compounds
  • * Human iPSC-derived cardiomyocytes, media, supplement, and coating kit

 

 

Axol Bioscience, coming to a conference near you

 

Our 2026 conference schedule is filling up fast. Come and see us if you're attending the following conferences.

 

 

Physiologically relevant iPSC-derived models

 

 

 

 

 

We use iPSCs to build more relevant models of human disease to expand your understanding and de-risk drug development.